Molecular Targeted Cancer Therapies and the Kidney

被引：0

作者：

Aksu, Ozge Bas ^{[1
]}

Sadioglu, Rezzan Eren ^{[2
]}

Sengul, Sule ^{[2
]}

机构：

[1] Ankara Univ, Dept Internal Med, Sch Med, Ankara, Turkey

[2] Ankara Univ, Dept Nephrol, Sch Med, Ankara, Turkey

来源：

TURKISH JOURNAL OF NEPHROLOGY | 2020年 / 29卷 / 03期

关键词：

Cancer; CAR-T; kidney; nephrotoxicity; onconephrology; targeted therapy; CYTOKINE RELEASE SYNDROME; T-CELL THERAPY; BRAF; HYPOMAGNESEMIA; TRASTUZUMAB; TOXICITIES; CETUXIMAB; RISK;

D O I：

10.5152/turkjnephrol.2020.4103

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Novel, targeted anticancer therapies have increased survival rates in patients. However, the incidence, severity, and pattern of their toxicities are different from those of traditional chemotherapies. The high prevalence of chronic kidney disease in the general population and the increased incidence of cancer highlight the need for nephrology consultation regarding this issue. Here, we review the incidence, mechanisms, and management of adverse renal effects associated with major molecular, targeted cancer therapies. Early diagnosis and prompt intervention in case of adverse renal events are crucial for the proper management of patients with cancer treated with targeted agents.

引用

页码：232 / 241

页数：10

共 49 条

[1] Renal Toxicities of Targeted Therapies [J].

Abbas, Anum ;

Mirza, Mohsin M. ;

Ganti, Apar Kishor ;

Tendulkar, Ketki .

TARGETED ONCOLOGY, 2015, 10 (04) :487-499

[2] Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanism [J].

Bellini, E. ;

Pia, A. ;

Brizzi, M. P. ;

Tampellini, M. ;

Torta, M. ;

Terzolo, M. ;

Dogliotti, L. ;

Berruti, A. .

ANNALS OF ONCOLOGY, 2011, 22 (04) :988-U1501

[3] Drug-Induced Reduction in Estimated Glomerular Filtration Rate in Patients With ALK-Positive Non-Small Cell Lung Cancer Treated With the ALK Inhibitor Crizotinib [J].

Brosnan, Evelyn M. ;

Weickhardt, Andrew J. ;

Lu, Xian ;

Maxon, Delee A. ;

Baron, Anna E. ;

Chonchol, Michel ;

Camidge, D. Ross .

CANCER, 2014, 120 (05) :664-674

[4] Toxicities of chimeric antigen receptor T cells: recognition and management [J].

Brudno, Jennifer N. ;

Kochenderfer, James N. .

BLOOD, 2016, 127 (26) :3321-3330

[5] Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis [J].

Cai, Jun ;

Ma, Hong ;

Huang, Fang ;

Zhu, Dichao ;

Bi, Jianping ;

Ke, Yang ;

Zhang, Tao .

WORLD JOURNAL OF SURGICAL ONCOLOGY, 2013, 11

[6] Meta-Analysis of Incidence and Risk of Hypomagnesemia with Cetuximab for Advanced Cancer [J].

Cao, Yunfei ;

Liao, Cun ;

Tan, Aihua ;

Liu, Lidan ;

Gao, Feng .

CHEMOTHERAPY, 2010, 56 (06) :459-465

[7] Identification of BRAF as a new interactor of PLCε1, the protein mutated in nephrotic syndrome type 3 [J].

Chaib, Hassan ;

Hoskins, Bethan E. ;

Ashraf, Shazia ;

Goyal, Meera ;

Wiggins, Roger C. ;

Hildebrandt, Friedhelm .

AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2008, 294 (01) :F93-F99

[8] Incidence and risk of hypomagnesemia in advanced cancer patients treated with cetuximab: A meta-analysis [J].

Chen, Peng ;

Wang, Long ;

Li, Hao ;

Liu, Bing ;

Zou, Zui .

ONCOLOGY LETTERS, 2013, 5 (06) :1915-1920

[9] Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors [J].

Cortazar, Frank B. ;

Marrone, Kristen A. ;

Troxell, Megan L. ;

Ralto, Kenneth M. ;

Hoenig, Melanie P. ;

Brahmer, Julie R. ;

Le, Dung T. ;

Lipson, Evan J. ;

Glezerman, Ilya G. ;

Wolchok, Jedd ;

Cornell, Lynn D. ;

Feldman, Paul ;

Stokes, Michael B. ;

Zapata, Sarah A. ;

Hodi, F. Stephen ;

Ott, Patrick A. ;

Yamashita, Michifumi ;

Leaf, David E. .

KIDNEY INTERNATIONAL, 2016, 90 (03) :638-647

[10] Two Hundred Years of Cancer Research [J].

DeVita, Vincent T., Jr. ;

Rosenberg, Steven A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (23) :2207-2214

← 1 2 3 4 5 →